Recent advances in understanding of lung cancer biology are outlined, with a focus on resistance mechanisms, tumor heterogeneity, plasticity, minimal residual disease, and the tumor microenvironment.
Abstract
Treatments for lung cancer have advanced significantly over the last 2 decades, improving survival and long-term outcomes. However, lung cancer mortality remains high, and cures for metastatic disease have remained elusive. Here, we outline recent advances in our understanding of lung cancer biology and areas of interest for future therapeutic development, with a focus on resistance mechanisms, tumor heterogeneity, plasticity, minimal residual disease, and the tumor microenvironment. A comprehensive understanding of how these areas influence tumor biology will be essential for the development of future lung cancer therapies and to improve the care of lung cancer patients.
Recent advances in understanding the disease and improving patient care include adding immune-based treatment to chemotherapy for widespread disease, using durvalumab after combined chemotherapy and radiation for disease limited to the chest, and introducing tarlatamab for cancer that has returned after prior treatment...
S. Peshin, E. Takrori, M. S. Mithani et al.· Cancers· 0 citations
Extending durable benefit and achieving cure in a broader population will require a deeper understanding of mechanisms of resistance, the development of novel immunotherapeutics, and more precise personalization of treatment strategies.
D. Boiarsky, N. Vokes· Cancer Journal· 0 citations
This review summarizes emerging therapeutic strategies for EOC, their mechanisms of action, and their potential to overcome treatment resistance, and covers molecularly targeted therapies, immunotherapies, metabolic and epigenetic approaches, cellular and gene therapies, targeted drug-delivery systems, and locoregional...
Zofia Pietrasik, Mikołaj Kapała, Joanna Pietrasik et al.· Cancers· 0 citations
With breakthrough findings in such a relatively short period of time, the treatment of patients with metastatic melanoma has become intensely personalized.
Shoshana T. Levi, Hannah A. Bank, J. Mullinax et al.· Hematology/Oncology Clinics...· 0 citations
The current standard of care is summarized and emerging strategies aimed at overcoming constraints aimed at overcoming these constraints are critically examined, including locoregional delivery technologies, immunotherapy, biomarker-defined precision approaches, and adaptive clinical trial designs.
Genaro R. Villa, Ashish D. Patel, D. Reardon et al.· Science Translational Medici...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
